The real story behind Trans Pacific Partnership trade deal is largely positive, writes Philip Stevens
Many countries have long recognized the absurdity of medicine tariffs, yet many countries persist with them
Pharmaceutical tariffs could be a barrier to access to medicines. This Working Paper looks at current levels of vaccine and pharmaceutical tariffs worldwide, and examines trade flows amongst the biggest exporting and importing nations.
Too many countries are jumping on the free healthcare bandwagon without first undertaking difficult but vital reforms of health infrastructure, writes Prof Kai Hong Phua.
Free Trade Agreements (FTAs) containing TRIPS-Plus intellectual property provisions have been widely criticised on the grounds they have the potential to raise medicine prices and undermine access to medicines, particularly in developing countries.
In the Trans-Pacific Partnership (TPP) negotiations, the U.S. and Japan have proposed that TPP partners increase their period of regulatory data protection (RDP) for biologic medicines to align with practice in other countries.
Brand competition, underpinned by intellectual property rights, is the key to ending the global fake medicines crisis.